Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To confirm safety and tolerability of global recommended phase three dose (RPTD) of
SAR245408 tablets when administered on continuous once daily dosing (CDD) in patients with
solid tumors.
Secondary Objectives:
- To evaluate the plasma pharmacokinetics (PK) of daily oral administration of SAR245408
in CDD treatment schedule in patients with solid tumors.
- To gather preliminary efficacy data after repeated administration of SAR245408 in
patients with solid tumors.